Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours

Gregory Kaltsas, Andrea Rockall, Dimitrios Papadogias, Rodney Reznek and Ashley B Grossman
Departments of Endocrinology and Academic Radiology, St Bartholomew’s Hospital, London EC1A 7BE, UK

Abstract
Neuroendocrine tumours (NETs) constitute a heterogeneous group of tumours that are able to express cell membrane neuroamine uptake mechanisms and/or specific receptors, such as somatostatin receptors, which can be of great value in the localization and treatment of these tumours. Scintigraphy with $^{111}$In-pentetreotide has become one of the most important imaging investigations in the initial identification and staging of gastro-enteropancreatic (GEP) tumours, whereas helical computed tomography (CT), magnetic resonance imaging (MRI), endoscopic and/or peri-operative ultrasonography are used for the precise localization of GEPs and in monitoring their response to treatment. Scintigraphy with $^{123}$I-MIBG (meta-iodobenzylguanidine) is sensitive in the identification of chromaffin cell tumours, although scintigraphy with $^{111}$In-pentetreotide may also have a role in the localization of malignant chromaffin cell tumours and medullary thyroid carcinoma; for further localization and monitoring of the response to treatment both CT and MRI are used with high diagnostic accuracy. More recently, positron emission tomography (PET) scanning is being increasingly used for the localization of NETs, particularly when other imaging modalities have failed, although its precise role and utility remain to be defined. Surgery is still the usual initial therapeutic, and only curative, modality of choice; however, the majority of NETs will require further treatment with somatostatin analogues and/or interferon; chemotherapy may be used for progressive and highly aggressive NETs, but its role has not been clearly defined. For those NETs that demonstrate uptake to a diagnostic scan with $^{123}$I-MIBG or $^{111}$In-octreotide, therapy with radionuclides such as $^{131}$I-MIBG or $^{111}$In/$^{90}$Y-octreotide or other isotopes, presents a further evolving therapeutic modality.

European Journal of Endocrinology 151 15–27

Introduction
Malignant neuroendocrine tumours (NETs) constitute a rare and heterogeneous group of tumours including the neuroendocrine adrenal, as well as endocrine islets within glandular tissue (thyroid or pancreatic) and cells dispersed between exocrine cells, such as endocrine cells of the digestive and respiratory tracts, known as carcinoid tumours (1). Carcinoid tumours have traditionally been classified further according to the anatomical site of origin: foregut, midgut and hindgut (2). Within these subgroups the biological and clinical characteristics of the tumours vary considerably (3). NETs can either be sporadic or occur as part of familial syndromes, mainly multiple endocrine neoplasia (MEN) I and II, Von Hippel Lindau (VHL) syndrome and neurofibromatosis (NF)-I, and have multipotent secretory capacities producing distinct clinical syndromes (4–6). In addition, they can express neuroamine uptake mechanisms and/or specific receptors, such as somatostatin (SS) receptors, at the cell membrane, which can be of great value in their localization and treatment (7). The majority of NETs exhibit an indolent growth pattern (well-differentiated NETs), but a substantial number may metastasize, mainly to the liver; a minority of NETs may be very aggressive and demonstrate a highly malignant course (poorly-differentiated NETs) (8). Scintigraphy with $^{111}$In-octreotide has become an imaging modality of major importance in the evaluation of gastro-enteropancreatic (GEP), islet cell or carcinoid tumours; whereas scintigraphy with $^{123}$I-MIBG (meta-iodobenzylguanidine) is of greater value in the evaluation of chromaffin cell tumours (pheochromocytomas and paragangliomas); scintigraphy with both $^{111}$In-octreotide and $^{123}$I-MIBG can also be used for medullary thyroid carcinoma (MTC) (8, 9). The use of these radiolabelled substances (radionuclides) is associated with a 67–100% sensitivity and may also identify other clinically unsuspected lesions and thus contribute...
to the overall staging of the disease (8–10). Further imaging with computed tomography/magnetic resonance imaging (CT/MRI) and/or ultrasonography will be required for the precise localization of NETs and for monitoring their response to treatment (11). Although positron emission tomography (PET) imaging is currently evolving as an alternative imaging method it is not at present widely available, and its precise role remains to be determined (12).

The initial management of NETs is surgical excision of the primary tumour (13). In the majority of patients who are not cured by surgery alone, medical therapy with agents such as somatostatin analogues and/or interferon-α is used to control the symptoms associated with specific humoral syndromes and may prevent tumour growth (14). Chemotherapy is currently mainly reserved for patients with aggressive, recurrent and/or progressive disease (8), whereas treatment directed against liver metastases is used in patients with excessive hepatic tumour load and uncontrollable symptoms (15–18). Specific therapy with radionuclides such as MIBG or somatostatin analogues appears promising for tumours which show diagnostic uptake, and has been increasingly used over the last decade. Further more experimental treatments, either alone or in combination with the existing ones, are under development (19, 20).

This review will focus on the ability of radionuclides to identify NETs, will identify recent advances in other imaging modalities, and will explore the rationale of using therapy with radiolabelled substances. The various radionuclides used, the results of observational and other prospective trials, their potential side-effects, and the integration of this treatment with other forms of treatment, will be discussed.

**Radionuclide and radiological imaging**

**Amine uptake and peptide receptor expression and visualization**

The demonstration of amine-uptake mechanisms and the high density of peptide receptors on NETs and their metastases has been used for both the diagnosis and monitoring of these tumours using techniques with radionuclides (21–23). Radionuclides provide a diagnostic modality in which radiolabelled amines or peptide analogues, after binding to suitable ligands, are utilized for the identification and localization of NETs (9). NETs and their metastases can be visualized in vivo using a γ-camera after the injection of various radionuclides, such as 123I-MIBG and 111In-pentetreotide (24–26). In addition, other small peptide receptors that are expressed in cell membranes of NET tissues include vasointestinal peptide (VIP), bombesin, cholecystokinin (CCK), gastrin and/or substance P (19, 20, 27, 28), and these can also be used as markers for in vivo tumour visualization (19, 20, 27).

**Scintigraphy with meta-iodobenzylguanidine (123I-MIBG)** MIBG is a guanidine derivative that exploits the type 1 uptake mechanism at the cell membrane, and is stored within intracellular storage vesicles (29, 30). MIBG localizes to adrenomedullary tumours, hyperplastic adrenal medulla and the healthy adrenal medulla; in addition, carcinoid tumours and MTC can also accumulate MIBG (31). The efficiency of 123I-MIBG is excellent for the visualization of intra-adrenal (phaeochromocytomas) and extra-adrenal (paragangliomas) chromaffin cell tumours, and can identify multiple tumours in patients with familial syndromes, showing a diagnostic sensitivity and specificity of around 90% (24, 31, 32). Occasionally, 123I-MIBG-negative malignant chromaffin cell tumors may demonstrate uptake to 111In-octreotide (33, 34). Scintigraphy with 131I-MIBG can also be used for the selection of patients for therapeutic MIBG based on a positive diagnostic scan; its sensitivity has been reported to be enhanced by the pre-imaging administration of ‘cold’ MIBG, although this remains controversial (35).

**Scintigraphy with 111In-octreotide** Somatostatin (SS) is a widely expressed peptide which mostly acts as an inhibitory factor after binding to specific somatostatin receptors (36). Because of its short half-life (1–2 min), many SS long-acting analogues, with a half life of 1.5–2 h and thus prolonged biological activity, have been synthesized, among which octreotide and lanreotide are the ones most commonly used (37, 38). SS analogues bind with high affinity to SS receptor subtypes 2 and 5 which are found in a large variety of NETs, adenocarcinomas, inflammatory and immune cells (18, 39). The most commonly-used SS analogue, octreotide, was initially conjugated with DTPA (diethylene-triamine-penta-acetic acid), but more recently to DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra-acetic acid) as a way of coupling SS analogues with various radioisotopes, mainly 111In (21, 26, 40). Scintigraphy with 111In-octreotide is superior to 111In-lanreotide and has a detection rate of 67–100% for all NETs; it can therefore be used for the diagnosis, staging and follow-up of patients with NETs (9, 41, 42). 111In-DTPA-Tyr3-octreotate, a newly synthesized SS analogue, demonstrated higher tumour uptake than 111In-DTPA-Tyr3-octreotide whereas kidney uptake remained similar (21, 43, 44). More recently, 68Ga coupled to octreotide or 64Cu-TETA-octreotide have been used as tracers for PET imaging, and have demonstrated more lesions than 111In-octreotide in patients with NETs (45, 46). Alternatively, scanning with radiolabelled VIP has been shown to be equally sensitive to 111In-octreotide in patients with GEP tumours (28, 47–49); in addition, other small peptide receptors expressed on the cell membranes of NET cells, such as those for bombesin, CCK, gastrin and/or substance P (47, 50), can also be used for...
in vivo tumour visualization (50). Finally, the superimposition of $^{111}$In-octreotide SPECT (single photon emission computerized tomography) with CT/MRI slices (anatomical-functional image fusion) has shown improved localization and characterization of NETs (51) (Fig. 1). However, at present, in spite of efforts aimed at developing more specific radioligands, $^{111}$In-octreotide remains the radionuclide of first choice for the imaging of NETs (27, 49).

**Recent advances in other imaging modalities in the diagnosis of various NETs**

Cross-sectional imaging techniques are used in the localization and staging of NETs and in assessing response to therapy. Many different imaging methods have been advocated, particularly for the localization of GEP tumours, which reflects the difficulties encountered in demonstrating these tumours which are usually small and inconspicuous. Direct comparison of imaging techniques is limited, as the differences in diagnostic performance often reflect techniques at different stages of development, and comparative series are usually small.

**Recent advances in ultrasound** Endoscopic ultrasound (EUS), with colour doppler, has a high sensitivity (79–100%) for the detection of small lesions in the pancreas (52, 53). Pancreatic endocrine tumours demonstrate abundant colour doppler signal, which may have pulsatile and/or continuous wave patterns (54). This marked vascularity may help to characterize

![Figure 1](https://www.eje.org)
advances in CT imaging of NETs

the advent of

tion is required.
laris layer (stage T3) and invasion into adjacent
sound may demonstrate invasion beyond the muscu-

hypoechoic submucosal mass (63). Endo-anal ultra-

sound demonstrates the lesion as a homogeneously
sion beyond the muscularis (60 –62). Endo-anal ultra-

fined to mucosa and submucosa) and T2 (invasion of
treatment of choice mainly for stage T1 (tumour con-
to the rectum, minimally invasive local resection, such
as transanal endoscopic microsurgery (TEM), is the
new technique it is not widely practised at present and
23 – 54 months (71). Although this is an interesting
recent series; in the same publication, dual-phase
MDCT without thin sections had a sensitivity of 57%
while in patients who underwent non-helical CT, the
sensitivity was only 29%; an overall diagnostic sensi-
tivity of 100% for combined dual-phase thin section
MDCT and endoscopic ultrasound has been reported
(69), although others have shown a sensitivity of
63% for the detection of pancreatic insulinomas using
multi-phase helical CT or MDCT alone (70).

Recently, 41 patients with hyperfunctioning phaeo-
chromocytomas were treated with a percutaneous
ethanol injection using CT-guidance, with disappear-
ance of the lesion in 31 patients and shrinkage or
complete necrosis in 10 patients, with follow-up over
23 – 54 months (71). Although this is an interesting
new technique it is not widely practised at present and
needs confirmation from studies including a larger
number of patients with more prolonged follow-up.

enteroclysis Small bowel enteroclysis is an estab-
lished technique for the diagnosis of small bowel mid-
gut carcinoids (72). The technique involves a tube
being passed into the distal duodenum through which
a large volume of contrast (usually barium) is intro-
duced. However, by providing only the luminal view
of the small bowel it may miss the primary tumour, dis-
ease in the mesenteric nodes, secondary mesenteric
masses and/or liver metastases (73, 74). CT enterocly-
sis (CT-E) combines the diagnostic information avail-
able from both small bowel enteroclysis and the
cross-sectional display provided by CT, thus demon-
strating luminal, mural and extraluminal abnormalities
in the small bowel. MDCT has enabled marked
improvements in CT-E, due to the multplanar refor-
mattion. This is a relatively new development, being
used in specialized centres, for the investigation of
small bowel lesions, and may have a role in the future in identifying the primary site of mid-gut carcinoids (75–77).

**CT fusion imaging** The ‘Hawkeye’ system combines the advantages of SPECT functional imaging with the anatomical resolution of CT (Fig. 1). The combined SPECT/CT device allows hybrid imaging using both SS scintigraphy and low-dose CT, providing well-localized functional information. This has two main advantages: first, functionally active areas can be co-located with possible sites of disease visible on CT, and secondly, physiological sites of tracer uptake can be clearly identified and thus discounted as sites of disease. One recent study using this technique demonstrated an increase in specificity for identifying NETs when compared with SPECT or CT alone; furthermore, 28% of patients had an alteration in treatment plan due to the image fusion results (51).

**New developments in MRI** Marked improvements in MRI technology have occurred over the past decade, resulting in improved diagnostic performance in the detection of NETs. In the chest, marked enhancement of bronchial carcinoids may create diagnostic difficulty on CT, as the appearance may mimic a pulmonary varix or pulmonary artery aneurysm, and a small vascular lesion may be overlooked or interpreted as a normal vessel (64). When a pulmonary lesion is suspected but cannot be seen on CT, MRI may play a role in localization. Bronchial carcinoids are of high signal intensity on T2-weighted and STIR images (‘short tau inversion recovery’, a T2-weighted sequence with fat suppression), allowing distinction between a small mass and the pulmonary vasculature of the central and middle third of the lung (78). In GEP lesions, a sensitivity of 94% for pancreatic lesions, but less for extra-pancreatic lesions, has been reported, with the best conspicuity of tumour usually on the T1 fat-saturated sequence (Fig. 2) (79, 80). MRI may also demonstrate the primary tumour mass in mid-gut carcinoids. In the largest reported series, the primary mass was identified in 8 of 12 patients with a gastrointestinal carcinoid (81). The best sequence for demonstrating the primary tumour was the post-gadolinium T1-weighted fat-suppressed image. MRI enteroclysis is also being developed, but currently this technique does not perform as well as CT-E and has not been used in the localization of primary mid-gut carcinoids (82). It may be used in the future, as the technique develops.

The liver-specific contrast agent, mangafodipir-trisodium (Mn-DPDP), may have a role in improved detection of neuroendocrine liver metastases. This is an intravenous contrast medium that is taken up by normal hepatocytes resulting in T1-brightening of the liver. Metastatic lesions are seen as low signal lesions against the bright liver parenchyma (Fig. 3). This technique is currently under investigation (83).

**Figure 2** Pancreatic insulinoma. CT images in the arterial phase (a) and the portal venous phase (b) do not clearly demonstrate the lesion in the pancreas (white arrows) in this case. However, T1-weighted MRI with fat saturation (c) clearly demonstrates the lesion (arrow) in the body of the pancreas, which has a low signal intensity against the high signal intensity of the normal pancreas.
In hind-gut carcinoids of the rectum, MRI may have a role in local staging of the primary mass, where endoanal ultrasound suggests extension of disease beyond the muscularis. MRI staging of rectal adenocarcinoma is now well established (84), but there are few data on MRI staging of carcinoid tumours at this site.

**Positron emission tomography (PET)**

Positron emission tomography utilizes the ability of radiolabelled tracers to be taken-up by certain tumours, and thus selectively assesses the function of different metabolic pathways of the specific tissue (85). It combines high sensitivity and reasonable resolution, and offers the ability to perform whole body scans (86, 87): $^{18}$F-labelled deoxyglucose (FDG) was the first tracer used, reflecting the increased glucose uptake in malignant tumours (86, 87). However, since NETs are mostly well-differentiated and slow-growing tumours, they have a low metabolic rate and cannot be visualized efficiently with this tracer (12, 86). Increased FDG uptake can be seen in less-differentiated NETs without SS receptors; in such cases the sensitivity of FDG-PET is clearly higher than that of scintigraphy with $^{111}$In-pentetreotide (86). The metabolic pathway synthesizing 5-hydroxytryptamine (5-HT) from 5-hydroxytryptophan (5-HTP) occurs in carcinoids and other NETs and can thus also be used for PET-imaging (85, 88, 89); $^{11}$C-5-HTP is specifically trapped by serotonin-producing tumours and this can be further enhanced by the concomitant administration of carbidopa (88). PET imaging using $^{11}$C-5-HTP has been shown to be superior to CT scanning in diagnosing GEP tumours and monitoring their response to therapy; for poorly-differentiated tumours FDG-PET can be used instead (86). Since scintigraphy with $^{111}$In-octreotide fails to visualize 10–20% of GEP tumours, PET may prove to be useful in certain cases, although this needs to be formally assessed by a prospective trial (90).

**Basic concepts involved in the application of radionuclide therapy to NETs**

Coupling a radioisotope to a molecule which would specifically bind to tumour cells could, in theory, deliver

![Figure 3](https://www.eje.org)
an effective radiation dose to the tumour without damage to non-tumour tissues (25, 91). Tumour heterogeneity may cause incomplete responses unless the radiation delivered can kill the nearby tumour cells that are target-negative; this depends on the cross-fire from the radioisotope localized in or on the target-positive tumour cells (23, 92). Radiiodine for treatment of thyroid disorders has been the best example of a radionuclide targeting agent with a high target-to-non-target ratio, rapid clearance of the unbound radioisotope, and a long residence time in the target (23). With the introduction of 131I-MIBG and, more recently, octreotide labelled with several radioisotopes, the field of treatment with radionuclides has been extended to a wide range of NETs (9, 23, 93). The patients’ responses to therapy are best evaluated using uniform criteria and are usually divided into symptomatic, hormonal and tumour responses according to World Health Organisation criteria (94).

### 131I-MIBG therapy for malignant NETs

Before using 131I-MIBG therapy a diagnostic 123I-MIBG scan is necessary to substantiate the avidity of tumour cells for the radionuclides (95). Imaging is performed after all medication known to interfere with MIBG uptake has been discontinued for at least one week prior to diagnostic scintigraphy or treatment (29, 94, 95). There is always free 131I present (albeit only a very small amount) in the administered material, so to minimize thyroidal 131I uptake, potassium iodide 120–150 mg/day is given starting 2 days before and continued for 8–21 days post-therapy (29, 94, 95).

**Results of treatment** Despite variations in selection criteria, dosimetry and therapeutic protocols, sufficient experience has now accumulated to confirm the efficacy of treatment with 131I-MIBG (24, 31, 94–96). Most centres have used between 100 and 300 mCi (3.7 and 11.1 GBq) 131I-MIBG per treatment; 131I-MIBG therapy is repeated, usually at 6-month intervals, until either complete remission is observed on either a diagnostic 123I-MIBG or no uptake is seen on a therapeutic 131I-MIBG scan, or the total dose is thought to be limiting in terms of toxicity, usually around 1–1.2 Ci (30, 94, 97).

**Malignant carcinoid tumours** The worldwide cumulative experience using 131I-MIBG treatment in 52 patients with metastatic carcinoid disease was reported in 1994: an objective tumour response was recorded in 15% with a symptomatic response in 65% of the patients (98). Since then, the results in another 47 patients have been reported demonstrating a 60% symptomatic and 12.5% hormonal response respectively, but with minimal reduction in tumour mass (94, 96, 99, 100).

**Malignant islet cell tumours** Very few cases of malignant islet cell tumours treated with 131I-MIBG have been reported, reflecting the relatively poor 123I-MIBG uptake of these tumours (94, 96). Scintigraphy with 111In-pentetreotide is more sensitive than scintigraphy with 123I-MIBG, and it is expected that treatment with 90Y-labelled SS analogues will be applicable to a larger population of patients with NETs, particularly islet cell tumours, and will also target the same lesions identified by 131I-MIBG; the results of phase II trials are now becoming available (101).

**Malignant MTC** The worldwide cumulative experience was reported in 1991 and 1994 for 18 and 22 patients respectively; an objective tumour response was documented in approximately 30% of patients with a symptomatic response in 50% (98, 102–104). Since then, a further 4 reports including 17 patients have appeared demonstrating a complete response in 1 patient plus two partial responses, while no response was obtained in the rest of the patients (31, 94, 99). Although tumour disappearance was exceptional, there was considerable improvement in symptoms with improved quality of life in the majority, with beneficial effects on hormonal and tumour control in a substantial number of patients (94, 97).

**131I-MIBG therapy for malignant chromaffin-cell tumours** The results of treatment with 131I-MIBG in 106 evaluable patients with malignant phaeochromocytomas was originally presented in 1991 (94, 98, 105). Since then the cumulative reported therapeutic response of 131I-MIBG therapy in patients with phaeochromocytomas and paragangliomas has been extensively reviewed (30, 95). In the majority of patients clinically symptomatic improvement relating to catecholamine hypersecretion was observed; a biochemical response was almost always associated with a symptomatic response. An overall tumour response (partial tumour response or stabilization of the disease) was obtained in 58% of the patients (30, 95, 96). The therapeutic response reported is quite heterogeneous, as it depends on several factors including tumour size and extension, 131I-MIBG tumour uptake and retention (30, 95).

**Toxicity** Haematological toxicity is the main significant side-effect of 131I-MIBG therapy (94). Severe myelosuppression is mainly seen in patients with widespread bone metastases and diffuse bone marrow involvement, and in patients heavily pretreated with chemotherapy (94, 106). Similarly, patients with widespread hepatic metastases should be observed carefully following 131I-MIBG therapy as transient hepatic failure can occur (31, 94).

**Future prospects** The integration of 131I-MIBG therapy with chemotherapy can be attempted to avoid the emergence of resistant clones which do not take up MIBG (24, 37, 107). However, in a recent prospective
Radionuclide therapy with $^{111}$In-octreotide

Mapping of the presence of various peptide receptors on the cell membrane by peptide receptor scintigraphy has become an evolving procedure which is non-invasive and requires only minor side-effects, and an easy-to-perform method in the selection of patients for therapy with radionuclides (20, 25).

Radionuclide therapy with $^{111}$In octreotide

$^{111}$In emits mainly $\gamma$-irradiation. Auger and conversion electrons, and exerts an anti-proliferative effect in malignant tumours if their principal target, cellular DNA, is within the particle range (44, 109, 110). Thirty end-stage patients with NETs, including 20 patients with GEP and 10 with MTC, were treated with $[^{111}\text{In-DTPA}]-\text{octreotide}$ (25). Six patients demonstrated a partial shrinkage of the tumour, whereas in another 8 patients there was stabilization of their disease; there was a tendency towards better results in patients with high tumour uptake (25); similar results have also been described in another 10 patients although an impairment in spermatogenesis was noted (44, 111). A further 27 patients were treated with $[^{111}\text{In-pentetreotide}]$, using two doses (180 mCi), with 62% and 81% obtaining a symptomatic and hormonal response respectively (112). Objective partial responses occurred in 2 (8%) patients and significant tumour necrosis in 7 (27%), without any major side effect, while the median survival was 18 months compared with the 6 months expected (112). However, recent studies have shown that the response may not be sustained over time, probably due to the preferential survival of resistant clones, and that its efficacy in large tumours and end-stage patients is limited (113). Therefore, it was suggested that $^{111}$In-octreotide should be given either in combination with $\beta$-emitters, or alone but only to eradicate micrometastases (44). Toxicity of the treatment was generally low with 100 GBq being the maximal tolerable dose (44).

Radionuclide therapy with $^{90}$Y-octreotide/DOTATOC

Radionuclides emitting $\gamma$-irradiation have greater therapeutic potential since the particles they emit have sufficient energy to cause cell damage, and they deliver higher radiation doses to a larger part of the tumour without penetrating very far into the surrounding tissue (23, 25, 114). The same SS analogue (Tyr3-octreotide) used for diagnosis has been coupled to a bifunctional chelating agent (DOTA) for the complexing of $^{90}$Y, a pure energetic $\beta$-emitter (19, 43, 44, 114, 115). The complex $^{90}$Y-DOTA-o-Phe$^1$-Tyr$^3$-octreotide ($^{90}$Y-SMT487, OctreoTher) (Novartis, Basel, Switzerland) is well suited for internal radiotherapy and, as it is mainly eliminated from the kidneys, it is administered with a concomitant intravenous infusion of amino-acids which reduce renal radioactivity without affecting the radionuclide uptake by the tumour (22, 25, 114, 116). There is also experience using $^{90}$Y-DOTATOC, a compound which appears to be similar to OctreoTher (117 – 119): of 10 patients with metastatic NETs treated with $^{90}$Y-DOTATOC, 6 reported an improvement in tumour growth, hormonal secretion and symptoms, with minimal side-effects, while the others showed stable disease (117). In total, 29 patients have been treated with $^{90}$Y-DOTATOC: 6 obtained a remission while 20 had disease stabilization (118, 119). In a phase II non-randomized study, 37 patients with GEP tumours, the majority of whom had resistant and progressive disease, were treated with 4 intravenous injections of $^{90}$Y-DOTA-o-Phe$^1$-Tyr$^3$-octreotide, up to a total of 6000 MBq/m$^2$ (120). An objective tumour response of 24% (36% for pancreatic tumours) was noted, without serious toxicity; there was also a suggestion of a more favourable outcome in the treated patients (120). Similar to the results in patients who received $^{111}$In-MIBG treatment, the main predictor of the outcome of therapy was the extent of the disease and the total tumour load (94). More recently, the results of 87 patients with NETs (57% had GEP and 16% MTC) treated with a cumulative activity ranging from 7.4 – 20.3 GBq were presented: a tumour response was obtained in 28% (5% complete response) with no major adverse effects up to a dose of 5.55 GBq/cycle (121). Other studies also involving the administration of DOTA-o-Phe$^1$-Tyr$^3$-octreotide in patients with NETs have mainly demonstrated a partial tumour response, while a considerable number showed disease stabilization (122); an overall partial response rate of around 20% has been documented in all these studies with a maximum cumulative dose being relatively less than the maximum tolerable dose (44). A Novartis-sponsored phase II study is...
currently ongoing to test the efficacy of OctreoTher in patients with a variety of disseminated NETs; it is hoped that the detailed results will be published soon (44, 114).

**Radiotherapy with 90Y lanreotide** Lanreotide shows a slightly different affinity to octreotide for SS receptors (122). Following a 25% regression of liver metastases and substantial symptomatic improvement in a patient with a malignant gastrinoma after four infusions of 1 GBq 90Y lanreotide, a phase IIa Multicentre Analysis of a Universal Receptor Imaging and Treatment Initiative (MAURITIUS) European study was organized, in which 39 patients with GEP tumours and 34 carcinoid tumours were included (123). After 2 cycles of 90Y-DOTA-lanreotide the treatment was discontinued in the case of progressive disease, otherwise another 2 cycles were given. Over a 3-year follow-up period, 20.5% of patients showed regression while 43.6% maintained stable disease (123). However, as 90Y-DOTA-d-Phe1-Tyr3-octreotide shows higher tumour uptake in patients with NET lesions compared with lanreotide, although this may be associated with increased haematological toxicity, the former appears at present to offer the more effective treatment (20). A few patients with MTC have also received 111In-octreotide or 90Y-lanreotide in the MAURITIUS trial (113, 123); although this was a not homogeneous group of patients, the initial results were encouraging, supporting further prospective studies for the use of this form of therapy in patients with advanced MTC disease.

**Radiotherapy with [177Lu-DOTA Tyr3] octreotate** In order to overcome the limitations of administering tumoricidal doses of radiotherapy to non-octreotide avid lesions, and the lack of uptake to certain areas due to tumour heterogeneity, several β-emitters, in addition to 90Y, such as 153Sm, 177Lu and 184Re, are also under consideration, usually in combination with the newest SS analogue, Tyr3-octreotide, which exhibits the highest affinity for SS receptor type 2 (19, 22, 44). 177Lu-DOTA-Tyr3-octreotate shows very high tumour uptake with a very good ratio of tumour-to-kidney uptake and can also be imaged by a γ-camera, thus suggesting an ideal compound for therapy with radionuclides (20, 44). Radiotherapy with 177Lu-DOTA-Tyr3-octreotate has recently been reported in 18 patients with a variety of progressive NETs, with 39% of patients showing a partial remission with minimal adverse effects (44, 124). It has also been suggested that in patients with tumours of different sizes, including small metastases, the administration of combinations of different radionuclides, e.g. 90Y which is optimal for larger tumours and 177Lu which is optimal for smaller tumours, coupled to octreotide and/or octreotide, may be particularly useful (19, 20, 124).

**Radioembolization** NETs show a particular predisposition for hepatic metastases which receive most of their blood supply from the hepatic artery, and hepatic administration of β-emitting radionuclides presents an attractive approach to deliver therapeutic focal irradiation (125, 126). Preliminary studies have shown that complications are low and, if the tumour pattern is nodular with some hypervascularity, beneficial results may develop both clinically and in terms of tumour burden (125, 126).

**Future prospects** For CCK-B receptor positive tumours, such as MTC, radiolabelled minigastrin analogues are currently under development (19). Multi-receptor tumour targeting using the combination of bombesin and neuropeptide Y (NPY) analogues is promising for both scintigraphy and therapy of tumours bearing such receptors (19). Peptides that can antagonize tumour angiogenesis by binding to α,β receptors of newly-formed blood vessels can also be used for both scintigraphy and treatment with radionuclides (127). To increase further tumoral uptake, hybrid peptides combining uptake via both SS receptors subtype 2 and α,β receptors have been constructed. Immune system activation for the control of micrometastatic disease may also be required to achieve complete control and eventual cure.

**Multidisciplinary approach** The increasing number of investigatory procedures and therapeutic options for both the diagnosis and treatment of malignant NETs is best dealt with by a multidisciplinary team. As patients with malignant NETs are rare, optimum management should be performed in centres with relevant experience and expertise. In order to evaluate the results of current management, establish guidelines and develop new therapeutic trials, multicentre collaborative protocols should be encouraged. This will limit the number of variations in therapy protocols to permit the interpretation of pooled data, particularly by establishing uniform entry, response and adverse reaction criteria, dose intervals and escalation of administered activity, and absorbed radiation dose.

**Conclusions** The localization of small NETs, assessing the extent of malignant lesions and monitoring response to therapy, remains a radiological challenge. Technological advances in cross-sectional imaging methods such as refinements in endoscopic ultrasound, multi-detector CT and MRI sequences have undoubtedly improved their accuracy. There is also promise being shown by newer ultrasound and MRI contrast agents in the staging of the disease. However, there is still a dearth of studies that produce valid results in comparing these
techniques and the choice of the most appropriate technique will depend on a constellation of several factors such as local expertise, availability and cost. Scintigraphy with 123I-MIBG and 111In-pentetreotide is routinely used for staging, often revealing clinically unsuspected lesions, and can affect the management of NETs that demonstrate uptake to these radionuclides. When considering therapy with radionuclides, the best radioligand should be carefully investigated. For all radionuclides used for therapy, long-term and survival statistics are not yet available and only partial tumour responses have been obtained using 131I-MIBG and 111In-octreotide. Initial results using 90Y-DOTA-lanreotide as well as 90Y-DOTA-d-Phe1-Tyr3-octreotide and/or 177Lu-DOTA-Tyr3-octreotide have indicated the possible clinical potential of radionuclides receptor-targeted radiotherapy, but side-effect profile analyses are not as yet fully available. In most cases receptor-mediated radiotherapy has been used in patients with an excessive tumour load and/or refractory disease, but it may also be the case that this form of treatment could be considered in patients with receptor-positive tumours to eradicate small amounts of residual disease or the presence of occult metastases. In order to minimize resistance and increase the efficacy of the treatment, further multicentre collaborative protocols with newly evolving treatments should be encouraged. Combination therapy with both 131I-MIBG and 90Y-labelled somatostatin analogues and 111In-, 90Y- and 177Lu labelled SS analogues remains an attractive theoretical option. It may be hoped that the efficacy of internal radiotherapy will be improved by co-administration of chemotherapeutic drugs whose radiosensitizing properties may be synergistic with that of irradiation.

References

5 Bravo EL. *Phaeochromocytoma*. *Cardiology Reviews* 2002 10 44–50.


689 Bombardieri E, Alliberti G, de Graaf C, Pauwels E & Crippa F. Positron emission tomography (PET) and other nuclear medicine modalities in staging gastrointestinal cancer. *Seminars in Surgical Oncology* 2001 20 134–146.


103 Hoefnagel CA, Delperat CC & Valdes Olmos RA. Role of $^{111m}$Tehalidobenzylguanidine therapy in malignant thyroid carcinoma. *Journal of Nuclear and Biological Medicine* 1991 **35** 314–336.

104 Troncone L, Ruini V, Mauzier ML, Valessa V, Daidone MS, Luzi S et al. The role of $^{111m}$Tehalidobenzylguanidine in the treatment of malignant thyroid carcinoma: results in five cases. *Journal of Nuclear and Biological Medicine* 1991 **35** 327–331.


108 Hoefnagel CA, Taal BG, Sivro F, Boot H & Valdes Olmos RA. Enhancement of $^{111}$In-MIBG uptake in carcinoid tumours by administration of unlabelled MIBG. *Nuclear Medicine Communications* 2000 **21** 753–761.


Received 30 December 2003
Accepted 30 March 2004